Clinical trials: Cancer Neck
Squamous Cell Carcinoma of the Head and Neck
Hyperbaric Radiation Sensitization of Head and Neck Cancers
There is reason to believe that hyperbaric oxygen administered immediately prior to radiotherapy will prove beneficial for this cancer type and stage.
- Trial name
- NCT03843671
- Testing
- Hyperbaric oxygen, Hyperbaric chamber
- Where
- 5 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- National Baromedical Services
Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
This is a Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
- Conditions
- Head and Neck Neoplasms, Carcinoma, Squamous Cell of Head and Neck, Metastasis, Recurrence
- Trial name
- NCT03799744
- Testing
- VCN-01, Durvalumab
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Institut Català d'Oncologia
Head and Neck Squamous Cell Carcinoma
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
In phase I of the trial, the investigators aim to explore the safety and feasibility of abemaciclib in combination with nivolumab in patients with recurrent/metatstatic head and neck squamous cell carcinoma (RM-HNSCC).
- Trial name
- NCT03655444
- Testing
- Abemaciclib, Nivolumab, Tumor biopsy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Cervical Cancer
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00980954
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 125 sites in United States, Canada and 2 more
- Volunteers
- 236 people
- Sponsor
- Radiation Therapy Oncology Group
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Persistent Disease
- Trial name
- NCT01267253
- Testing
- Brivanib Alaninate, Laboratory Biomarker Analysis
- Where
- 43 sites in United States
- Volunteers
- 31 people
- Sponsor
- Gynecologic Oncology Group
Head and Neck Cancer
Treatment Selection According to Skin Reaction to Cetuximab
The therapy of patients with locally advanced head and neck cancer will be adjusted to the grade of skin rush as recorded after the first two cycles of Cetuximab and Cisplatin, i.e.
- Trial name
- NCT01472653
- Testing
- cisplatin, radiotherapy, cetuximab
- Where
- Slovenia
- Volunteers
- 120 people
- Sponsor
- Institute of Oncology Ljubljana
Patient Reported Outcome Measures, Colorectal Cancer
Predicting Disease Progression and/or Recurrence in Cancer
This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer…
- Conditions
- Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer
- Trial name
- NCT04776837
- Testing
- Observational Cohort
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
Head and Neck Cancer, Cancer of the Head and Neck
Fluorescence Imaging in Head and Neck Cancer
Fluorescent technology continues to advance in the detection of sentinel lymph nodes (SLNs). Currently, this requires switching from near-infrared light to white light to be able to identify the fluorescent tissue contrasting…
- Trial name
- NCT03297957
- Testing
- Hands-free goggle system
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
Lymphedema of Leg, Cancer of Cervix
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
The aim of the study is to explore the feasibility and safety of High Intensity Interval Training on a stationary bike for patients with lymphedema in the lower limbs and the role of compression garments during exercise.
- Conditions
- Lymphedema of Leg, Cancer of Cervix, Cancer, Ovarian, Cancer, Endometrial
- Trial name
- NCT03653819
- Testing
- First exercise session + compression, First exercise session - compression
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Herlev and Gentofte Hospital
Cervical Cancer
Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer
In recurrent advanced cervical cancer, patients were prone to drug resistance who have relapsed within prior platinum-based chemotherapy.
- Trial name
- NCT06455072
- Testing
- Nituzumab, Serplulimab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
This phase I trial studies the side effects and best dose of TLR8 Agonist VTX-2337 when given together with cetuximab in treating patients with locally advanced, recurrent, or metastatic squamous cell cancer of the head and neck…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01334177
- Testing
- TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
Low Risk, Papillary Thyroid Cancer
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.
- Conditions
- Low Risk, Papillary Thyroid Cancer, Radiofrequency Ablation
- Trial name
- NCT07140757
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Colon Cancer, Esophageal Carcinoma
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
The purpose of this study is to evaluate the safety and efficacy of EpCAM-specific CAR T Cells infusion for EpCAM positive Cancer.
- Conditions
- Colon Cancer, Esophageal Carcinoma, Pancreatic Cancer, Prostate Cancer
- Trial name
- CARTEPC (NCT03013712)
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Chengdu Medical College
Human Papilloma Virus, Cervical Dysplasia
Educational Video's Impact on Knowledge Regarding Cervical Cancer Screening
The researchers will be conducting a prospective randomized trial where the researchers will be introducing an educational video to see whether there is an increase in knowledge scores surrounding cervical cancer, cervical cancer…
- Trial name
- NCT05756192
- Testing
- Educational video
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- George Washington University
Mouth Cancer
Wild Type p53 Adenovirus for Oral Premalignancies
Primary Objectives: 1. To determine the maximum tolerated dose and transduction efficiency of adenoviral mediated wild type p53 gene transfer in premalignancies of the upper aerodigestive tract. 2.
- Trial name
- NCT00410865
- Testing
- INGN 201
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Cancer, Oropharyngeal Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Background: The human papillomavirus (HPV) can cause a number of cancers, including cervical and throat cancers. The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white…
- Conditions
- Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer
- Trial name
- NCT01585428
- Testing
- Fludarabine, Cyclophosphamide, Young TIL
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Impact of the Oral Microbiota on Relapse in HNSCC Patients
to characterise the impact of microbiota in radiotherapy efficacy
- Trial name
- MICR-ORL (NCT06807034)
- Testing
- buccal swabs
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Sainte Catherine
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene).
- Trial name
- NCT05241834
- Testing
- LOXO-260
- Where
- 16 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Cervical Cancer
Folate and Protection Against Cervical Cancer
This is a randomised double-blind placebo-controlled trial to see whether giving a low dose of the vitamins folic acid and riboflavin is beneficial to women who have very low grade abnormalities of the cervical cells.
- Trial name
- NCT00220532
- Testing
- Folic acid with riboflavin
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.